HGTS 7/29/88 
After extensive discussion with the investigators, the Subcommittee unanimously 
approved a motion made by Dr. Neiman as follows: 
"Consideration of the protocol should be deferred until animal model testing is 
completed, to include: 
"1 . Transfer of the vector to tumor infiltrating lymphocytes or TIL from a suitable 
murine tumor system; 
"2. Detection of vector-marked TIL in recipient mice; 
"3. Analysis of retroviral replication, tumorigenesis, and other undesirable 
effects in recipient mice; 
"In addition, data should be presented demonstrating that: 
"1 . The human TIL that are marked by the vector are representative of the 
relevant cell populations, and; 
"2. ’Dry run’ tests with human TIL should be completed which demonstrate a 
lack of infectious helper virus by the most sensitive assays available. 
Respectfully submitted, 
I hereby certify that, to the best of my 
knowledge, the foregoing Minutes and 
Attachments are accurate and complete. 
Chair 
Human Gene Therapy Subcommittee 
[184] 
Recombinant DNA Research, Volume 13 
